ArticleCancers2025

High HER2 Intratumoral Heterogeneity Is Resistant to Anti-HER2 Neoadjuvant Chemotherapy in Early Stage and Locally Advanced HER2-Positive Breast Cancer.

Takaaki Hatano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.